K

Kaken Pharmaceutical Co Ltd
TSE:4521

Watchlist Manager
Kaken Pharmaceutical Co Ltd
TSE:4521
Watchlist
Price: 4 376 JPY 0.3% Market Closed
Market Cap: 165.7B JPY
Have any thoughts about
Kaken Pharmaceutical Co Ltd?
Write Note

Kaken Pharmaceutical Co Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Kaken Pharmaceutical Co Ltd
Operating Income Peer Comparison

Comparables:
4502
4568
4578
4519
4503

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
K
Kaken Pharmaceutical Co Ltd
TSE:4521
Operating Income
ÂĄ9B
CAGR 3-Years
-19%
CAGR 5-Years
-19%
CAGR 10-Years
-6%
Takeda Pharmaceutical Co Ltd
TSE:4502
Operating Income
ÂĄ403B
CAGR 3-Years
-17%
CAGR 5-Years
13%
CAGR 10-Years
12%
Daiichi Sankyo Co Ltd
TSE:4568
Operating Income
ÂĄ260.5B
CAGR 3-Years
51%
CAGR 5-Years
19%
CAGR 10-Years
7%
Otsuka Holdings Co Ltd
TSE:4578
Operating Income
ÂĄ353.6B
CAGR 3-Years
19%
CAGR 5-Years
33%
CAGR 10-Years
5%
Chugai Pharmaceutical Co Ltd
TSE:4519
Operating Income
ÂĄ540.2B
CAGR 3-Years
15%
CAGR 5-Years
24%
CAGR 10-Years
21%
Astellas Pharma Inc
TSE:4503
Operating Income
ÂĄ130.6B
CAGR 3-Years
-1%
CAGR 5-Years
-13%
CAGR 10-Years
-1%

See Also

What is Kaken Pharmaceutical Co Ltd's Operating Income?
Operating Income
9B JPY

Based on the financial report for Jun 30, 2024, Kaken Pharmaceutical Co Ltd's Operating Income amounts to 9B JPY.

What is Kaken Pharmaceutical Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
-6%

Over the last year, the Operating Income growth was 24%. The average annual Operating Income growth rates for Kaken Pharmaceutical Co Ltd have been -19% over the past three years , -19% over the past five years , and -6% over the past ten years .

Back to Top